JNK
JNK is a stress-activated MAPK that phosphorylates the N-terminal transactivation domain of c-Jun and regulates proliferation, apoptosis, motility, metabolism, and DNA repair[1]. Mechanistically, MKK4 and MKK7 increase JNK activity through phosphorylation, linking development and stress responses to downstream transcriptional control[2]. In disease models, dysregulated JNK signaling contributes to neurodegeneration, chronic inflammation, cancer, ischemia/reperfusion injury, and apoptosis-related pathology[1][3]. Compared with related isoforms, JNK1 and JNK2 are widely expressed, whereas JNK3 is mainly expressed in the brain, with lower expression in heart and testis[4]. This isoform distinction is experimentally important because JNK3 disruption protected mice from kainic acid-induced seizure activity and hippocampal neuronal apoptosis[5]. For experimental applications, SP600125 provides a reversible ATP-competitive JNK inhibitor that blocks JNK1/2/3 and supports pathway-dissection studies, although inhibitor-based conclusions require target-specific validation[6].
References:
- [1]. Johnson GL, et al. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta. 2007 Aug;1773(8):1341-8. [Content Brief]
- [2]. Los AP, et al. Protein kinase C inhibits binding of diacylglycerol kinase-zeta to the retinoblastoma protein. Biochim Biophys Acta. 2007 Mar;1773(3):352-7. [Content Brief]
- [3]. Cui J, et al. JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin. 2007 May;28(5):601-8. [Content Brief]
- [4]. Nakano R, et al. Biological Properties of JNK3 and Its Function in Neurons, Astrocytes, Pancreatic β-Cells and Cardiovascular Cells. Cells. 2020 Jul 29;9(8):1802. [Content Brief]
- [5]. Yang DD, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 1997 Oct 23;389(6653):865-70. [Content Brief]
- [6]. Bennett BL, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6. [Content Brief]
-
JNK Related Products (377)
Related Products (377)
-
Antibodies (8)
-
Acenocoumarol-d5
0 ImagesCat. No.: HY-B1014SCAS No.: 1185071-64-0Acenocoumarol-d5 is the deuterium labeled Acenocoumarol (HY-B1014). Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase.
-
Paeonolide (Standard)
0 ImagesCat. No.: HY-N2156RCAS No.: 72520-92-4Paeonolide (Standard) is the analytical standard of Paeonolide (HY-N2156). This product is intended for research and analytical applications. Paeonolide, found in Paeonia suffruticosa, is an ERK1/2 activator. Paeonolide promotes early and late osteoblast differentiation, stimulates pre-osteoblast transmigration, and activates the BMP-Smad1/5/8, Wnt-β-catenin, JNK and p38 pathways. Paeonolide can be used for the research of osteoporosis, periodontitis.
-
Roburic acid (Standard)
0 ImagesRoburic acid (Standard) is the analytical standard of Roburic acid. This product is intended for research and analytical applications. Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a Ki of 7.066 μM against human TNF, an IC50 of 9 μM against human COX-2, and an IC50 of 5 μM against ovine COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6 in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases.
-
Berberine
0 ImagesBerberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine (Natural Yellow 18) induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine (Natural Yellow 18) has antineoplastic properties. The sulfate form (HY-N0716B) improves bioavailability.
-
Keracyanin chloride (Standard)
0 ImagesCat. No.: HY-105935RCAS No.: 18719-76-1Synonyms: Cyanidin 3-rutinoside chloride (Standard); Cyanidin 3-O-rutinoside chloride (Standard); Sambucin chloride (Standard)Keracyanin (chloride) (Standard) is the analytical standard of Keracyanin (chloride). This product is intended for research and analytical applications. Keracyanin chloride inhibits NF-κB/FAK/MAPK signaling pathway. Keracyanin chloride exhibits antioxidant, anti-inflammatory and hypoglycemic effects, and is orally active.
-
Halicin (Standard)
0 ImagesCat. No.: HY-107597RCAS No.: 40045-50-9Synonyms: SU3327 (Standard)Halicin (Standard) is the analytical standard of Halicin (HY-107597). This product is intended for research and analytical applications. Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt Kinase.
-
Tamarixetin (Standard)
0 ImagesTamarixetin (Standard) is the analytical standard of Tamarixetin. This product is intended for research and analytical applications. Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC50 of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and AKT pathways.
-
Sinapaldehyde (Standard)
0 ImagesSinapaldehyde is a methoxyphenol and a selective COX-2 inhibitor (IC50: 47.8 µM) that can be extracted from various plants. Sinapaldehyde has antibacterial, anti-inflammatory, and antioxidant activities. Sinapaldehyde can scavenge DPPH free radicals (IC50: 172 μM). Sinapaldehyde is active against both Gram-negative and Gram-positive bacteria.
-
Silybin B-d3
0 ImagesCat. No.: HY-N7046SSynonyms: Silibinin B-d3Silybin B-d3 (Silibinin B-d3) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity.
-
Vanillylamine (Standard)
0 ImagesCat. No.: HY-W097899RCAS No.: 1196-92-5Vanillylamine is an immediate precursor for capsaicinoids. Vanillylamine is a derivative of Vanillin (HY-N0098) is synthesized through a transaminase reaction in the phenylpropanoid pathway of capsaicinoid synthesis. Vanillylamine significantly alleviates myelosuppression caused by abdominal and pelvic tumor chemotherapy.
-
Imidapril hydrochloride (Standard)
0 ImagesSynonyms: TA-6366 (Standard)Imidapril (hydrochloride) (Standard) is the analytical standard of Imidapril (hydrochloride). This product is intended for research and analytical applications. Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions.
-
ASP3026 (Standard)
0 ImagesASP3026 (Standard) is the analytical standard of ASP3026. This product is intended for research and analytical applications. ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research.
-
Murrayafoline A (Standard)
0 ImagesCat. No.: HY-W100287RCAS No.: 4532-33-6Murrayafoline A (Standard) is the analytical standard of Murrayafoline A (HY-W100287). This product is intended for research and analytical applications. Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.
-
AEG3482 (Standard)
0 ImagesCat. No.: HY-107599RCAS No.: 63735-71-7AEG3482 (Standard) is the analytical standard of AEG3482 (HY-107599). This product is intended for research and analytical applications. AEG3482 is a potent antiapoptotic compound that inhibits Jun Kinase (JNK) activity through induced expression of heat shock protein 70 (HSP70). AEG3482 directly binds HSP90, thereby facilitating HSF1-dependent expression of HSP70 and HSP25.
-
Liensinine (Standard)
0 ImagesLiensinine (Standard) is the analytical standard of Liensinine (HY-N0484). This product is intended for research and analytical applications. Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke.
-
CDKi free base
0 ImagesCat. No.: HY-W259575CAS No.: 70035-83-5CDKi free base is a CDK inhibitor. CDKi free base induces morphological changes, DNA fragmentation, and cell death in vestibular schwannoma cells. CDKi free base downregulates pRb, EGF-R, PI3K, NF-κB, and Shh levels, while upregulating JNK, ASK1, Caspase 3, and p21, and induces PARP-1 cleavage. CDKi free base can be used in research related to vestibular schwannoma.
